| Literature DB >> 36160824 |
Mohamed Essa1, Frank Meyer2, Robert Damm3, Zuhir Halloul1.
Abstract
Aim: The aim of this study was to investigate short-/long-term vascularsurgical patency and the outcome in chronic mesenteric ischemia (CMI) depending on the mesenteric revascularization technique and reflecting real-world data.Entities:
Keywords: Antegrade/retrograde reconstruction; Chronic mesenteric ischemia; One-/ two-vessel reconstruction; Open reconstruction
Year: 2021 PMID: 36160824 PMCID: PMC9421703 DOI: 10.1159/000519423
Source DB: PubMed Journal: Visc Med ISSN: 2297-4725
Fig. 1Contrast-enhanced multi-slice CT showing a CT-slice of a sagittal reconstruction in a patient with high-grade stenosis of the CA at its origin (>70% reduction of arterial diameter) and occlusion of the proximal SMA (left) and a 3-D reconstruction of the same patient (right) − red arrow represents the CA-stenosis, and light blue arrow represents the SMA-occlusion (from the Department of Radiology and Nuclear Medicine, University Hospital of Magdeburg [Germany]). SMA, superior mesenteric artery.
Fig. 2Selective angiography representing a long-standing obstruction of the SMA with well-developed collaterals through the GDA (CA: yellow arrow, GDA: blue arrow, and SMA: red arrow) (from the Department of Radiology and Nuclear Medicine, University Hospital of Magdeburg [Germany]). SMA, superior mesenteric artery.
Anatomical distribution for pathologies of celiac axis (celiac), SMA, and IMA
| Occluded/stenotic | Patients, |
|---|---|
| Celiac/SMA/IMA | 12 (31.6) |
| Celiac/SMA | 17 (44.7) |
| SMA/IMA | 6 (15.8) |
| Celiac/IMA | 1 (2.6) |
| SMA | 0 |
| Celiac | 2 (5.3) |
Celiac, celiac axis; SMA, superior mesenteric artery; IMA, inferior mesenteric artery.
Fig. 3Frequency of various inflow feeding arteries used for reconstruction.
Fig. 4Distribution according to the type of material used for mesenteric reconstruction (polyester/dacron, ePTFE, vein graft, biologic/xenogenic material, combined reconstruction, and others/endarterectomy).
Morbidity and mortality (early postoperatively, at 1 year and 5 years) with their correlation to preoperative risk factors
| Analyzed risk factor | Morbidity/mortality | ||
|---|---|---|---|
| early postoperative | at 1 year | at 5 years | |
| Gender | 0.358/0.132 | 0.594/0.164 | 0.280/0.714 |
| Age | 0.411/0.791 | 0.591/0.724 | 0.388/0.359 |
| Diabetes mellitus | 0.652/0.196 | 0.930/0.139 | 0.829/0.438 |
| Arterial hypertension | 0.652/0.207 | 0.233/0.166 | 0.280 |
| BMI | 0.536/0.289 | 0.456/0.361 | 0.324/0.449 |
| HLP | 0.632/0.100 | ||
| Preoperative TPN | 0.215/0.915 | 0.809/0.918 | 0.308/0.185 |
| History of smoking | 0.173/0.475 | 0.583/0.504 | 0.197/0.333 |
| PAD | 0.200/0.220 | ||
| Cerebrovascular disease | 0.970/0.314 | 0.157/0.454 | 0.255/0.310 |
| Renovascular disease | 0.220/0.565 | 0.962/0.504 | 0.732/0.155 |
| CHD | 0.359/0.074 |
| 0.130 |
| CHF | 0.103/0.648 | 0.254/0.436 | 0.412/0.268 |
| CRF | 0.096/0.416 | 0.886/0.353 | 0.088/0.464 |
| Previous malignancy | 0.191/0.925 | 0.07/0.919 | |
| Previous abdominal surgery | 0.874/0.523 | 0.901/0.558 | 0.952/0.310 |
| Previous bowel surgery | 0.163/0.585 | 0.870/0.453 | 0.914/0.398 |
| Previous peripheral vascular surgery | 0.489/0.380 | 0.318/0.139 |
|
| Previous carotid surgery | 0.946/0.295 | 0.294 | 0.412/0.268 |
| Previous aortic surgery | 0.739/0.362 | 0.308/0.185 | |
| Previous cardiac surgery | 0.765 |
| 0.231/0.104 |
| Previous mesenteric surgery | 0.583/0.436 | 0.732/0.919 | |
BMI, body mass index; HLP, hyperlipoproteinemia; TPN, total parenteral nutrition; PAD, peripheral arterial disease; CHD, coronary heart disease; CHF, congestive heart failure; CRF, chronic renal failure.
Statistically significant.
Postoperative outcome and complications and their correlation to both the directionality of reconstruction (antegrade vs. retrograde) and the number of reconstructed vessels (1-vessel vs. 2-vessel)
| Antegrade ( | Retrograde ( | 1-vessel ( | 2-vessel ( | |
|---|---|---|---|---|
| Primary patency − early postoperative, %, | 90.5, 19 | 90.5, 19 | 85, 17 | 77.8, 14 |
| 0.207 | 0.687 | |||
| Primary patency − at 1 year, %, | 92.3, 12 | 100, 9 | 92.9, 13 | 100, 8 |
| 1.0 | 1.0 | |||
| Primary patency − at 5 years, %, | 100, 4 | 100, 4 | 100, 8 | |
|
| ||||
| Cardiac complications, %, | 14.3, 3 | 0 | 5, 1 | 11.1, 2 |
| 0.238 | 0.595 | |||
| Respiratory complications, %, | 38.1, 8 | 47.1, 8 | 30, 6 | 55.6, 10 |
| 0.743 | 0.188 | |||
| Renal complications, % | 9.5, 2 | 23.5, 4 | 10, 2 | 22.2, 4 |
| 0.378 | 0.395 | |||
| Hepatobiliary complications, %, | 9.5, 2 | 47.1, 8 | 5, 1 | 22.2, 4 |
| 0.743 | 0.188 | |||
| Cerebrovascular complications, %, | 28.6, 6 | 11.8, 2 | 15, 2 | 27.8, 5 |
| 0.257 | 0.438 | |||
| Bleeding, %, | 38.1, 8 | 41.2, 7 | 25, 5 | 55.6, 10 |
| 1.0 | 0.096 | |||
| Bleeding required reoperation, %, | 38.1, 8 | 41.2, 7 | 25, 5 | 55.6, 10 |
| 1.0 | 0.096 | |||
| Peripheral ischemia, %, | 9.5, 2 | 0 | 0 | 11.1, 2 |
| 0.492 | 0.218 | |||
| Postoperative urinary tract infection, %, | 14.3, 3 | 29.4, 5 | 20, 4 | 22.2, 4 |
| 0.426 | 1.0 | |||
| Gastrointestinal bleeding, %, | 4.8, 1 | 17.6, 3 | 10, 2 | 11.1, 2 |
| 0.307 | 1.0 | |||
| Wound infection, %, | 19, 4 | 11.8, 2 | 10, 2 | 22.2, 4 |
| 0.672 | 0.383 |
Fig. 5Cumulative survival comparing 1-vessel and 2-vessel groups.
Patients' characteristics noted in previous reports and in the current study [17, 20, 21, 23, 24, 25, 28, 32, 33, 34, 37, 38, 39, 40, 41, 42], in alphabetic order
| Author | Sex ratio (m/f) | Mean age, years | Weight loss, | Smoking, | PAD, |
|---|---|---|---|---|---|
| Beebe et al. [ | 7/10 | 54 | 10/10 (100) | Not reported | Not reported |
| Calderon et al. [ | 17/20 | 59 | 13/20 (65) | 6/20 (30) | 3/20 (15) |
| Current study | 20/38 (53) | 64 | 32/38 (84) | 39/38 (78.9) | 23/38 (60.5) |
| Davenport et al. [ | 119/156 | 65 | 54/156 (35) | 77/156 (49) | 37/156 (24) |
| Foley et al. [ | 31/49 | 62 | Not reported | 48/49 (98) | 28/49 (57) |
| Gentile et al. [ | 16/26 | 59 | Not reported | 25/26 (96) | 16/26 (62) |
| Geroulakos et al. [ | 9/10 | 66 | 10/10 (100) | Not reported | Not reported |
| Hollier et al. [ | 11/56 | 50 | 55/56 (98) | Not reported | Not reported |
| Jimenez et al. [ | 33/47 | 62 | 39/47 (83) | 43/47 (91) | 23/47 (49) |
| Johnston et al. [ | 11/21 | 58 | 1/21 (5) | 19/21 (90) | 17/21 (81) |
| Kihara et al. [ | 30/42 | 60 | Not reported | 37/42 (88) | Not reported |
| Kruger et al. [ | 22/39 | 65 | 37/39 (95) | 36/39 (92) | 16/39 (41) |
| Mateo et al. [ | 60/85 | 62 | 74/85 (87) | 75/85 (88) | Not reported |
| McMillan et al. [ | 17/25 | 61 | 21/25 (84) | 22/25 (88) | 9/25 (36) |
| Moawad et al. [ | 19/24 | 58 | 14/24 (58) | 20/24 (83) | Not reported |
| Rheudasil et al. [ | 21/41 | 59 | 23/41 (56) | 36/41 (88) | 18/41 (44) |
| Zelenock et al. [ | 13/23 | 56 | 23/23 (100) | Not reported | Not reported |
Postoperative outcome of the current study and of previous reports at the follow-up period [23, 38, 40, 41, 43, 44, 45, 46]
| Author | Patients, | Technical success (%) | Mortality (%) | Morbidity (%) | Recurrence (%) | 1° patency (%) |
|---|---|---|---|---|---|---|
| Cho et al. [ | 25/41 | 100 | 0 | 21 | Not reported | 57 |
| Current study | 38/55 | 100 | 13.2 | 48.4 | 4.5 | 81.6 |
| Foley et al. [ | 28/28 | 100 | 3 | Not reported | 10 | 79 |
| Illuminati et al. [ | 11/12 | 100 | 0 | 27 | 10 | 90 |
| Kihara et al. [ | 42/52 | 100 | 10 | 35 | 10 | 65 |
| Kruger et al. [ | 39/67 | 100 | 2.5 | 12 | 5 | 92 |
| Leke et al. [ | 17/25 | 100 | 6 | 41 | 0 | 100 |
| Mateo et al. [ | 85/not reported | 100 | 8 | 23 | 20 | 71 |
| Park et al. [ | 98/179 | 100 | 5 | 21 | 8 | Not reported |